Skip to main content

PLEASE NOTE: For everyone’s safety, Fasken recommends anyone on-site at our Canadian offices be familiar with the COVID-19 recommendations in place which may include one or more of the following: social distancing, hand sanitizing, wearing a mask in common areas and proof of full vaccination. These measures apply to lawyers, staff, clients, service providers and other visitors.

Client Work

JJR IV Acquisition and BIOX Corporation complete amalgamation

Fasken
Reading Time 1 minute read Subscribe

Overview

Client

JJR IV Acquisition Inc.

On March 1, 2010, JJR IV Acquisition Inc. and BIOX Corporation completed their previously announced amalgamation which resulted in the reverse take over of JJR. The amalgamation and certain related matters were approved at shareholder meetings of JJR and BIOX, each held on February 25, 2010. Prior to the Amalgamation, each outstanding common share of JJR was consolidated on a 24 to 1 basis.

In connection with the completion of the Qualifying Transaction, the common shares of BIOX will be listed on the Toronto Stock Exchange on March 2, 2010 under the symbol "BX" and the common shares of JJR will be de-listed from the TSX Venture Exchange.

JJR was advised in this transaction by a team from Fasken Martineau that included, among others, Rubin Rapuch, Tracy Hooey, Jeff Hergott and Alex Nikolic.

Team

    Subscribe

    Receive email updates from our team

    Subscribe